COMPLETED

Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage

Talk to us

Conditions

Actinic KeratosesPhotodamageaging faceactinic keratosisBBLPDTphotodynamic therapy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To provide a treatment of both actinic keratoses and photodamage within one treatment.

Official Title

Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage

Quick Facts

Study Start:2025-06-27
Study Completion:2025-12-29
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT07053852

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Over 18yrs of age
  2. * Willingness to participate in all required study activities and visits
  3. * Willingness to sign the informed consent form
  4. * Visible and palpable signs of diffuse actinic damage and actinic keratoses of mild to moderate severity located on the face
  5. * Significant signs of photoaging, evaluated by investigator, that include any or all the following:
  6. * Dyspigmentation
  7. * Solar lentigines
  8. * Telangiectasias
  9. * Diffuse erythema
  10. * Roughness and other textural changes
  11. * Fine lines
  12. * Wrinkles
  13. * Actinic bronzing
  1. * Subject who is unable and unwilling to provide consent for study schedule and procedures
  2. * Subject who is pregnant or trying to become pregnant during the study
  3. * Subjects using any topical treatment on their AKs; must stop at least one month prior
  4. * Subjects currently undergoing cancer treatment with medical or radiation therapy
  5. * Subjects with a known hypersensitivity to 5-aminolevulinic acid or any component of the study material
  6. * Subjects with history of a photosensitivity disease, such as porphyria cutanea tarda

Contacts and Locations

Study Locations (Sites)

Rochester Dermatologic Surgery
Victor, New York, 14564
United States

Collaborators and Investigators

Sponsor: Sherrif Ibrahim

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06-27
Study Completion Date2025-12-29

Study Record Updates

Study Start Date2025-06-27
Study Completion Date2025-12-29

Terms related to this study

Keywords Provided by Researchers

  • aging face
  • actinic keratosis
  • BBL
  • PDT
  • photodynamic therapy

Additional Relevant MeSH Terms

  • Actinic Keratoses
  • Photodamage